Asset Details
Do you wish to reserve the book?
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Do you wish to request the book?
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost-effectiveness analysis of 21-valent pneumococcal conjugated vaccine among adults in Canada
2025
Overview
A 21-valent pneumococcal conjugate vaccine (PCV21) was recently authorized in Canada to protect adults against invasive pneumococcal disease (IPD).
To assess the cost-effectiveness of PCV21 compared to current Canadian vaccination recommendations for adults of different age and risk groups.
We used a static cohort model to estimate lifetime incremental cost-effectiveness ratios (ICERs), in 2023 Canadian dollars per quality-adjusted life year (QALY), discounted at 1.5 %, in population cohorts aged 33 (midpoint of the 18–49 year age group), 50, and 65 years from the health system and societal perspectives. The primary analysis used 2022 serotype distributions for IPD cases. Additional analyses incorporated indirect effects from pediatric vaccination and used IPD serotype distributions from 2015 to 2019, to explore the impact of changes over time observed in some age groups.
For population groups currently recommended to receive PCV20 in Canada (65 years and older, 50–64 years with additional risk factors for IPD, or 18–49 years with immunocompromising conditions), PCV21 was cost-effective at a $50,000 per QALY threshold and dominated PCV20 in most scenarios when PCV21 serotypes were more prevalent. When PCV20 serotypes were equally or more prevalent than PCV21 serotypes, results were more sensitive to assumptions about indirect effects and serotype replacement. For groups not currently recommended a conjugate vaccine (50–64 years without additional IPD risk factors and 18–49 years with chronic medical conditions or unhoused populations), use of a higher-valency conjugate vaccine was a cost-effective intervention compared to no vaccination, with the optimal vaccine dependent on the proportion of IPD attributable to PCV20 and PCV21 serotypes in the population of interest. Results were sensitive to vaccine price in most scenarios.
The use of PCV21 may be cost-effective in some populations, depending on the prevalence of IPD serotypes covered by PCV20 and PCV21.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adult
/ Adults
/ Age
/ Aged
/ Canada
/ Female
/ Humans
/ Invasive pneumococcal disease
/ Male
/ PCV20
/ PCV21
/ Pneumococcal Infections - economics
/ Pneumococcal Infections - epidemiology
/ Pneumococcal Infections - prevention & control
/ Pneumococcal Vaccines - administration & dosage
/ Pneumococcal Vaccines - economics
/ Pneumococcal Vaccines - immunology
/ prices
/ risk
/ Streptococcus pneumoniae - immunology
/ Vaccines
/ Vaccines, Conjugate - administration & dosage
/ Vaccines, Conjugate - economics
/ Vaccines, Conjugate - immunology
/ Valency
